We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.10 | 9.70 | 10.50 | 10.10 | 10.10 | 10.10 | 177,070 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.83 | 93.71M |
Date | Subject | Author | Discuss |
---|---|---|---|
05/3/2019 13:10 | only any " net " positions are hedged in the market... You've been told this a million times, which is why the orders are sometimes shown on the tape, and other times they aren't, it all comes down to a brokers NET position, yet you still cant grasp it... oh well, you cant put 2 pints into a 1 pint pot. Anyway, back in the real world. | tosh123 | |
05/3/2019 13:08 | Inanaco - assume you're only talking about moditope in your previous post? If so I don't think anybody at all has an issue with the fact that they want to carry out a phase I/II trial before considering any deals on Modi1. It's exactly the same business model as countless other baby bios use and the same strategy as they adopted for SCIB1. It obviously makes sense as the valuation of any deal will be higher after a proof of concept study. Just to be clear though, you use the term selling off but I think you mean licensing. Selling wouldn't generate milestones and royalties whereas licensing would. | bermudashorts | |
05/3/2019 13:04 | >let's see who is actually capable of generating any sensible discussion<<br /> Well it's not you LOL! | gazza | |
05/3/2019 13:03 | Gazza Its an opinion that you did not write ... !!! that is the point here ... your opinions get left on the shelf the discussions on here all revolve around my opinion ...good or bad lol thanks for proving the point .... you needed me to create your thread I refer to my first post inanaco5 Mar '19 - 11:12 - 20209 of 20214 Edit 0 0 0 Definitely becoming the go to place for moaners !! ADFVN SCLP let's see who is actually capable of generating any sensible discussion | inanaco | |
05/3/2019 12:57 | it's actually a Cliff edge ... the vaccine does not depreciate its in tolerance or Not ... | inanaco | |
05/3/2019 12:54 | Even C7 is calling him out on ADVFN: Inan: >and vaccine's don't get pulled tendons <<br /> C7: >No, but vaccines do go off, lol. It is called depreciation.<< LOL. Just thought I'd balance it with another of your "quality" posts! | gazza | |
05/3/2019 12:44 | Look at me, look at my posts, aren't they wonderful, no one else can post like me, I'm the best. If it wasn't for the self-congratulatory, smug preface it would be an OK post. Nothing unique in it, nothing novel and it is after all, just an opinion. | gazza | |
05/3/2019 12:04 | LOL ... pity you cannot post like this tosh .. because if you could you would ... Tosh still trying to find the 2 x 26,000 cfd contract .. LOL ATB -------------------- the problem with selling off years ago, scancell would have sold an incomplete vaccine ..in other words the earlier version .. at the "time" .. would work PauseUnmute .. but in only maybe 40% of patients because Scancell would have received milestone's and end point Royalties that would have cost shareholders an absolute fortune ... Great Data makes something Valuable ... mouse data then human ... when you are breaking into a "brand new sector" which is what Autophagy is ... you need a Compelling data profile .... Modi1 which is why BioNtech are collaborating ... with an End Point Deal ... Scancell get to the highest point of value in the chain, but cannot take it further without spending the kind of cash on infrastructure that BioNtech has ... Clean Rooms are very expensive !! when you are handling and manipulating patients blood which has to be partly reinfused back together with the machinery to handle 100's of patients which is why siemens plays such a significant part so selling years ago ... would have cost us the TCR program delay in getting Modi1 as a very advanced vaccine has actually helped us ... in 2012 the vaccine was "easy" to make .. not now its a hydrophobic peptide conjugate | inanaco | |
05/3/2019 11:22 | " Sensible discussion " ? that's you counted out then, so you had just as well crawl back under your rock. Bye. | tosh123 | |
05/3/2019 11:12 | Definitely becoming the go to place for moaners !! ADFVN SCLP let's see who is actually capable of generating any sensible discussion | inanaco | |
05/3/2019 10:55 | Loz, it is without doubt ( IMHO ) people trying to average down, and thats not necessarily a bad thing. I don't see any other II getting involved until there is something concrete on the books. | tosh123 | |
05/3/2019 09:33 | Well a "significant premium" to 6p could be 8p - a bargain compared to the last two placings. There is a subtle/significant difference between someone "wanting to buy" and someone "needing to sell". | gazza | |
05/3/2019 09:28 | Bermuda, according to the very respected Wildforce and Inanaco anyone wanting to buy a stake in Scancell would have to pay a very significant premium to the current share price whatever that might be. Are you intimating that someone can pick up 5% of the Company without having to pay a premium. | panama7 | |
05/3/2019 09:16 | Tosh - I, *WE ALL* understand.... I think there is 'much frustration' ATM Having said that, the 'frustration' will increase - if March is allowed to pass without some indication of 'progress' Leaving just another month of 'cash-burn' to ponder ATB | the real lozan | |
05/3/2019 09:15 | Tosh, Would be great but I can just imagine the outrage if the BOD bought 21m shares at 6p - remember the stick John Chiplin got for buying at 10p? Hopefully the whole fund will be taken on by another company but if they do need to liquidate then the very best scenario is a seamless transfer to a decent ii. IMO of course. The sooner City Financial give some clarity on their position the better though. It's an added complication if Scancell are considering a funding round within the next few months. | bermudashorts | |
05/3/2019 09:07 | Loz, i appreciate that, hence the appendix " that was never going to happen ". My point was that a display of confidence would have countered any damage caused by the City announcement, and that had the BOD of been able to, buying the 21 mill would have been a great move. | tosh123 | |
05/3/2019 08:54 | agree Lozan | bermudashorts | |
05/3/2019 08:41 | Good morning Tosh et al - I don't think "our BOD { or anyone else } IS in a position to hoover up any or all of those 21 mil+ shares" at the moment, as they are not FOR SALE {at the moment} Even IF the BOD could afford to do so | the real lozan | |
05/3/2019 08:06 | Tosh, yes, the old ones are the best. Room for both ends of the spectrum here lol. | gazza | |
05/3/2019 08:05 | Kreature, thats made me laugh out loud. | tosh123 | |
05/3/2019 08:01 | Has the 2013 trade sale started yet ? | kreature |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions